Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),...
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)...
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic...
FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing...
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE...
CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards...
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) --...
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu)...
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product...
Director Share PurchaseLONDON, UK / ACCESSWIRE / February 22, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical...
NES-ZIONA, ISRAEL / ACCESSWIRE / February 21, 2024 / Mike Williams made a name for himself making difficult endzone catches...
UDENYCA ONBODY™ UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvFull Prescribing Information, including instructions for use, is...
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively...
Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid...
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio...
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell...
CHICAGO, IL / ACCESSWIRE / February 19, 2024 / The American Society for Transplantation and Cellular Therapy® (ASTCT®) supports the...
LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on...